Invitation to the EBAC-accredited satellite symposium 'Navigating therapeutic approaches in HCM: Unravelling recent evidence', at ESC HF 2024, Lisbon, Portugal.

For more information, please visit the ESC website.

Learning Objectives

Educational Objectives

• Recognize clinical scenarios indicative of the need for an HCM-specific therapeutic approach
• Evaluate the most recent clinical data on the application of myosin inhibitors in treating HCM among patients with heart failure
• Deliberate on the supporting evidence and focused recommendations outlined in recently published guidelines concerning hypertrophic cardiomyopathy

Agenda

Chair: Roberto Barriales-Villa, MD, PhD – A Coruña, Spain

12:30 – 12:40  Welcome and introduction - Roberto Barriales-Villa, MD, PhD – A Coruña, Spain

12:40 – 12:50 Epidemiology and clinical features of hypertrophic cardiomyopathy - Perry Elliott, MD, PhD – London, United Kingdom

12:50 – 13:00 Cardiac physiology and pathophysiology of HCM, including peak oxygen Uptake (pVO2) - Ahmad Masri, MD – Portland, OR, USA

13:00 - 13:10 Myosin inhibitors: recent clinical data and applications in HCM and HF - Caroline Coats, MD – Glasgow, United Kingdom

13:10 – 13:20 Precision medicine and focused recommendations in HCM guidelines - Ahmad Masri, MD – Portland, OR, USA / Roberto Barriales-Villa, MD, PhD – A Coruña, Spain

13:20 – 13:30 Panel discussion and Q&A - All faculty

CME Accreditation

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)  for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.

Funding

This symposium is supported by an unrestricted educational grant from Cytokinetics.